Collagen-based implant materials with central agent depot for the therapy of bone defects

原位组织工程（TE）的概念可以开辟新的治疗选择，例如广泛或不愈合的骨缺损。与传统的TE相比，没有细胞植入，因此这种植入的成本和审批工作更低。目前的转移项目建立在已完成的SFB/Transregio 79的子项目M4（建立用于骨缺损愈合的新方法‘原位组织工程’）的基础上，并将与应用伙伴一起进一步发展在临床中使用的概念。在TR79后期，一种由矿化胶原蛋白制成的仿生骨替代材料被开发出来，该材料在中央仓库中装载了化学吸引物质。可以证明，与未修饰的支架相比，在水环境中建立的浓度梯度刺激间充质干细胞和内皮细胞向支架的迁移，从而促进缺陷愈合。转移项目现在的重点是(1)将支架生产转移到临床批准的马胶原蛋白和工业上可行的工艺链上，(2)研究用于控制药物释放的替代储存成分，目的是扩大含药植入物的应用范围，(3)探索新的，合适的策略来引入药物仓库。(4)研究含有药物沉积的植入物的灭菌性和保质期，(5)从缺氧条件培养基中生产化学吸引药物混合物的标准化，(6)测试用于局部释放抗生素的支架系统的可用性。一家受人尊敬的胶原蛋白医疗设备制造商被选为应用合作伙伴。转让项目的基础是坚实的筹备工作和SFB/TR 79工作所产生的大量出版物

The concept of in situ tissue engineering (TE) could open up new treatment options, e.g. for extensive or non-healing bone defects. In contrast to the classic TE, no cells are implanted, so that the costs and the approval effort for such implants are lower. The present transfer project builds on the work of sub-project M4 (Establishment of the new approach `in situ tissue engineering΄ for bone defect healing) of the completed SFB/Transregio 79 and is to further develop the concept investigated there with an application partner for use in the clinic. At the end of TR79, a biomimetic bone substitute material made of mineralized collagen has been developed, which is loaded with chemoattractive substances in a central depot. It could be shown that the concentration gradient established in an aqueous environment stimulates the migration of mesenchymal stem cells and endothelial cells into the scaffold and thus promotes defect healing compared to unmodified scaffolds.The focus of the transfer project is now (1) the transfer of scaffold production to clinically approved, equine collagen and the development of an industrially feasible process chain, (2) the investigation of alternative depot components for controlled drug release with the aim of expanding the range of applications of the drug-containing implants, (3) the exploration of new, suitable strategies for the introduction of the drug depot, (4) the study of the sterilisability and shelf life of implants containing the drug deposit, (5) the standardization of the production of chemoattractive drug mixtures from hypoxia-conditioned medium and (6) the testing of the usability of the scaffold system for the local release of antibiotics. A respected manufacturer of collagen-based medical devices was won as an application partner.The transfer project is based on solid preparatory work and a large number of publications that have resulted from the work in the SFB/TR 79